Gastric adenocarcinoma results from an interaction between chronic infection, environmental and dietary exposures, host genetic susceptibility, and, in a small minority, high-penetrance germline variants. Chronic Helicobacter pylori infection, an IARC group 1 carcinogen, is the dominant modifiable cause. It accounts for approximately 75% of attributable risk overall and approximately 90% of non-cardia (distal) cancers.[1][2] Most intestinal-type cancers arise through the stepwise Correa cascade (chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → carcinoma). Diffuse-type cancers frequently arise without a recognizable precancerous lesion. When diffuse-type cancer is hereditary, it is driven by germline CDH1 (E-cadherin) inactivation.[3] About 10% of cases show familial clustering, but only about 1–3% are attributable to a known heritable germline variant.[4] The TCGA molecular classification (EBV-positive, MSI, genomically stable, chromosomal instability) has superseded older, undifferentiated oncogene lists as the framework for molecular etiology.[5]
H. pylori is the single most important and most modifiable cause of gastric adenocarcinoma.
IARC classified it as a group 1 carcinogen in 1994 and reaffirmed this classification in 2009.[2][6]
Attributable risk: approximately 75% of global gastric cancer and approximately 90% of non-cardia cancers. In Japan, fewer than 1% of gastric adenocarcinomas are considered unrelated to H. pylori.[1][7]
Anatomic specificity: the association is strong for non-cardia cancer (pooled OR approximately 2.97) and essentially null for cardia cancer (OR approximately 0.99).[8]
Test method affects measured risk:serology reflects lifetime infection and yields higher odds ratios than histology. Histology underestimates infection when atrophic gastritis has reduced the bacterial load.[2]
Low absolute risk per infected person: about 44% of adults worldwide are infected, but only about 1–3% of infected individuals develop gastric cancer. Strain virulence, host genetics, and co-exposures modulate this risk.[1][9]
Mechanism (Correa cascade): chronic infection causes the following changes, which drive progression from normal mucosa to carcinoma:[10][11]
Induction of activation-induced cytidine deaminase, with TP53 mutation
Virulence factors: CagA (delivered through the type IV secretion system) and VacA, particularly the s1/m1 genotype, confer substantially higher risk than less virulent strains.[11] CagA also activates the NLRP3 inflammasome, which shapes immune-cell infiltration in gastric cancer.[12]
Histologic subtype:H. pylori is associated with both intestinal-type and diffuse-type cancer. Chronic inflammation is not required for diffuse-type carcinogenesis, which implies a distinct mechanism.[1]
Causal evidence: a cluster-randomized trial in Linqu County, China, enrolled 180,284 participants with 11.8 years of follow-up. Community-based eradication reduced gastric cancer incidence (intention-to-treat HR 0.86; 95% CI 0.74–0.99). The effect was larger among participants with confirmed eradication (HR 0.81; 95% CI 0.69–0.96).[13][14]
HDGC is an autosomal dominant syndrome of early-onset diffuse gastric cancer and lobular breast cancer. It is caused mainly by inactivating germline CDH1 variants.[18][19]
Pathogenic CDH1 variants occur in approximately 1 in 5,000 to 1 in 8,000 people in unselected populations.[19]
Mechanism:CDH1 encodes E-cadherin, a transmembrane cell–cell adhesion protein and tumor suppressor.
Carriers inherit one inactivated allele.
A somatic second hit (mutation, loss of heterozygosity, or promoter hypermethylation) inactivates the remaining allele.
Current penetrance estimates (lower than older pedigree-based figures of approximately 70% in men and 56% in women):[18][19]
Cumulative gastric cancer risk to age 80: approximately 37–42% in men and 25–33% in women
Lobular breast cancer risk in women: 37–55%
Intramucosal foci: nearly all carriers harbor microscopic intramucosal (pT1a) signet ring cell foci. Cancer of any stage is found in 88–97% of risk-reducing gastrectomy specimens, but disease ≥pT1b is found in only about 2–3%. Modeled lifetime risk of advanced (≥stage 2) cancer is approximately 10% in men and 6.5% in women.[19]
Other HDGC genes:CTNNA1 (α-E-catenin) accounts for approximately 2% of HDGC families. About 70% of clinically defined HDGC families have no identified causative gene.[3][4]
The TCGA classification defines four molecular subtypes with distinct causal mechanisms.[5]
TCGA molecular subtypes of gastric adenocarcinoma
Subtype
Approximate frequency
Defining features
Chromosomal instability (CIN)
~50%
Aneuploidy; frequent TP53 mutation; receptor tyrosine kinase amplification (ERBB2, VEGFA, FGFR2); mostly intestinal type; often at the GEJ
Microsatellite instability (MSI)
~22%
Mismatch-repair deficiency, commonly from MLH1 promoter hypermethylation; high tumor mutational burden
Genomically stable (GS)
~20%
Diffuse-type histology; CDH1 and RHOA mutations; CLDN18–ARHGAP fusions; peritoneal spread
EBV-positive
~9%
Extensive hypermethylation; PIK3CA and ARID1A mutations; PD-L1 overexpression
The Asian Cancer Research Group (ACRG) proposed an overlapping classification: MSI, MSS/EMT, MSS/TP53-active, and MSS/TP53-inactive. Its distinct MSS/EMT subtype is marked by CDH1 loss and peritoneal tropism.[22]
In routine practice, formal subtype assignment is not yet standard. Only actionable markers are tested: MMR/MSI, HER2, PD-L1, and increasingly EBV and Claudin-18.2.[4][23]
Up to about 25% of GEJ tumors fall outside the expected CIN class.[24]
Apply the H. pylori causal link to non-cardia cancer only. Cardia and GEJ cancers are instead linked to obesity, reflux, and Barrett's esophagus.[8][7]
A single negative histologic H. pylori test can be falsely negative in atrophic gastritis or intestinal metaplasia; serology captures lifetime infection.[2]
Diffuse-type cancer often does not follow the Correa cascade.[1]
The following findings should prompt germline CDH1 evaluation per NCCN criteria:[19]
Diffuse gastric cancer or T1a signet ring cell carcinoma at any age
Diffuse gastric cancer diagnosed before age 50
Lobular breast cancer with a personal or family history of diffuse gastric cancer
↑IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994). "Schistosomes, liver flukes and Helicobacter pylori". IARC Monogr Eval Carcinog Risks Hum. 61: 1–241. PMID7715068.
↑Liabeuf D, Oshima M, Stange DE, Sigal M (April 2022). "Stem cells, Helicobacter pylori, and mutational landscape: utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer". Gastroenterology. 162 (4): 1067–1087. doi:10.1053/j.gastro.2021.12.252. PMID34942172Check |pmid= value (help).
↑Pan KF, Li WQ, Zhang L, Liu WD, Ma JL, Zhang Y, et al. (November 2024). "Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial". Nat Med. 30 (11): 3250–3260. doi:10.1038/s41591-024-03153-w. PMID39079993Check |pmid= value (help).
↑Graziano F, Humar B, Guilford P (December 2003). "The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice". Ann Oncol. 14 (12): 1705–13. doi:10.1093/annonc/mdg486. PMID14630673.
↑Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. (May 2015). "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes". Nat Med. 21 (5): 449–456. doi:10.1038/nm.3850. PMID25894828.
↑Walch HS, Borpatragohain R, Jee J, Chatila W, Fong C, Maron SB, et al. (May 2025). "Clinical implications of The Cancer Genome Atlas molecular classification system in esophagogastric cancer". Clin Cancer Res. 31 (10): 1912–1921. doi:10.1158/1078-0432.CCR-24-3473. PMID40299774Check |pmid= value (help).